Please login to the form below

Not currently logged in
Email:
Password:

Pfizer halts osteoarthritis trial

Pfizer has suspended its global phase III clinical trials programme testing the investigational painkiller tanezumab in osteoarthritis

Based on a request from the US Food and Drug Administration (FDA), Pfizer has suspended its global phase III clinical trials programme testing the investigational painkiller tanezumab in osteoarthritis. The FDA's request was based on a small number of reports of osteoarthritis worsening in subjects taking the drug, sometimes even leading to the need for joint replacement.

The adverse event has not been observed in tanezumab patients in clinical programmes for other indications, the company noted. However, at the FDA's request, Pfizer will meet with the agency this week "to present its assessment of the potential implications of the adverse events in the osteoarthritis programme for the other tanezumab clinical programmes."

The programmes include ongoing studies in patients with cancer pain, interstitial cystitis, chronic low back pain and diabetic peripheral neuropathy.

The clinical hold, which is effective immediately, suspends the recruitment of new osteoarthritis patients and the dosing of existing osteoarthritis subjects, as well as dosing of patients with osteoarthritis in other studies.

Tanezumab is a humanised monoclonal antibody directed against nerve growth factor. It was acquired by Pfizer when the company bought the biotech firm Rinat in 2006.

The announcement of the suspension of the tanezumab programme comes directly on the heels of other negative safety-related news for Pfizer. Earlier this week, the company said it would withdraw its cancer drug Mylotarg (gemtuzumab ozogamicin) from the US at the request of the FDA after postmarketing data found that the drug, which was approved based on surrogate endpoints under the FDA's accelerated approval programme, was not as safe or effective as it appeared to be in pre-marketing studies.

24th June 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics